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Laboratories and Clinical Trial Management, Rotterdam, The Netherlands; 7Universitäts-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany; 8Southlake Regional
Health Centre, Newmarket, Ontario, Canada; 9Hospital Ramón y Cajal, Madrid, Spain; 10Békés Megyei Pándy Kálmán Kórház County Hospital, Gyula, Hungary; 11Tokuda
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Aims To evaluate long-term safety and efficacy of ticagrelor monotherapy in patients undergoing percutaneous coronary
interventions (PCIs) in relation to chronic obstructive pulmonary disease (COPD) at baseline and the occurrence




This is a non-prespecified, post hoc analysis of the randomized GLOBAL LEADERS trial (n = 15 991), comparing the
experimental strategy of 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)
after PCI with the reference strategy of 12-month DAPT followed by 12-month aspirin monotherapy. Impact of
COPD and dyspnoea AE (as a time-dependent covariate) on clinical outcomes was evaluated up to 2 years. The
primary endpoint was a 2-year all-cause mortality or non-fatal, centrally adjudicated, new Q-wave myocardial in-
farction. The presence of COPD (n = 832) was the strongest clinical predictor of 2-year all-cause mortality after
PCI [hazard ratio (HR) 2.84; 95% confidence interval (CI) 2.21–3.66; P adjusted = 0.001] in this cohort (n = 15 991).
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No differential treatment effects on 2-year clinical outcomes were found in patients with and without COPD (pri-
mary endpoint: HR 0.88; 95% CI 0.58–1.35; P = 0.562; P int = 0.952). Overall, at 2 years dyspnoea was reported as
an AE in 2101 patients, more frequently among COPD patients, irrespective of treatment allocation (27.2% in ex-
perimental arm vs. 14.5% in reference arm, P = 0.001). Its occurrence was not associated with a higher rate of the
primary endpoint (P adjusted = 0.640) in the experimental vs. the reference arm.
...................................................................................................................................................................................................
Conclusion In this exploratory analysis, COPD negatively impacted long-term prognosis after PCI. Despite higher incidence of
dyspnoea in the experimental arm, in particular among COPD patients, the safety of the experimental treatment
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Introduction
Patients with coronary artery disease (CAD) and chronic obstructive
pulmonary disease (COPD) represent a population at increased risk
for adverse clinical events, periprocedural complications, comorbid-
ities, and polypharmacy.1–3 In PLATO, dual antiplatelet therapy
(DAPT) consisting of ticagrelor and aspirin reduced the composite
primary endpoint of cardiovascular death, myocardial infarction (MI),
or stroke in patients with acute coronary syndromes (ACS), com-
pared with clopidogrel and aspirin. However, ticagrelor increased the
incidence of dyspnoea, which may lead clinicians to withhold ticagre-
lor from COPD patients.4 In ACS patients with COPD, the absolute
risk of ischaemic events at 1 year was reduced with ticagrelor vs. clo-
pidogrel, without significantly increasing the risk of major bleeding
events.5 In stable CAD patients with COPD, ticagrelor has not yet
been specifically evaluated, neither as a part of DAPT nor as a single
antiplatelet agent.6,7
Chronic obstructive pulmonary disease has been recognized as a
condition associated with an altered platelet function which may af-
fect the efficacy of adjunctive antiplatelet regimen after percutaneous
coronary interventions (PCIs), including the recently advocated
aspirin-free antiplatelet strategies.8
While GLOBAL LEADERS did not demonstrate any safety sig-
nal associated with ticagrelor monotherapy use, as indicated by
the close to unity upper boundary of confidence interval (CI) of
the primary endpoint,9 the risk-to-benefit balance may substantial-
ly differ among patients with concomitant COPD and patients
experiencing dyspnoea that might lead to lower treatment
adherence.
Therefore, it is of interest to evaluate the impact of COPD on
long-term clinical outcomes after PCI in a contemporary large-scale
all-comers randomized clinical trial, and to assess the efficacy and
safety of ticagrelor monotherapy in these patients in relation to
COPD status at baseline and occurrence of an important drug-
related adverse effect of ticagrelor—dyspnoea.
Methods
Patient population
The GLOBAL LEADERS (ClinicalTrials.gov, identifier: NCT01813435)
was an investigator-initiated, prospective, randomized, multicentre, multi-
national, open-label trial comparing two strategies of antiplatelet treat-
ment in a large all-comers population scheduled for PCI.9 A total of
15 991 patients with either stable CAD or ACS were randomly allocated
either to an experimental strategy of 1 month aspirin and ticagrelor, fol-
lowed by 23 months ticagrelor alone, or to the reference strategy with
1 year DAPT consisting of 75–100 mg aspirin daily in combination with ei-
ther 75 mg clopidogrel daily (for patients with stable CAD) or 90 mg tica-
grelor twice daily (for patients with ACS), followed by 75–100 mg aspirin
alone for 12 months.10 Detailed inclusion, exclusion criteria and study
procedures were described previously and are presented in the
Supplementary material online, Appendix.10 The trial was performed in
compliance with the ethical principles of the Declaration of Helsinki, the
International Conference of Harmonization, and Good Clinical Practice.
All participants provided written informed consent at the time of
enrolment.
In the present post hoc analysis, we report the clinical outcome of
patients undergoing PCI in relation to COPD status (documented at
baseline) and the occurrence of dyspnoea adverse event (AE) during the
2-year follow-up. In addition, exploratory landmark analyses for assessing
onset of dyspnoea were performed at 30 days, since ticagrelor-related
dyspnoea predominantly occurs within the first 30 days of treatment, be-
tween 31 and 365 days, when ticagrelor-related dyspnoea occasionally
occurs, and between 366 and 730 days, when other reasons for dyspnoea
such as heart failure are more likely explanations.11,12 Chronic obstruct-
ive pulmonary disease was defined as a chronic lung disease requiring a
long-term use of bronchodilators or steroids, as defined in the
EuroSCORE (Supplementary material online, Appendix).
Adherence was assessed by direct pill counts and self-reporting.9,10
Patient was considered adherent in case there was no evidence of
randomized treatment discontinuation prior to follow-up visits scheduled
at 30 days, 3, 6, 12, 18, and 24 months after the index procedure9,10
(Supplementary material online, Appendix). Revascularizations and


































































































per-protocol restart of DAPT allowed: (i) ticagrelor and aspirin for
30 days in the experimental treatment strategy group, (ii) DAPT with tica-
grelor and aspirin (ACS, stable CAD patients already on ticagrelor or pra-
sugrel), clopidogrel and aspirin (stable CAD) for 365 days in the standard
treatment strategy group.1
Study endpoints
The primary endpoint comprised a composite of all-cause death or ECG-
core-lab adjudicated, new Q-wave MI up to 2 years after the index pro-
cedure.9,13,14 Deaths from any cause were ascertained without adjudica-
tion. Q-wave MI was defined according to the Minnesota
classification.13,14 The key safety endpoint was site reported Bleeding
Academic Research Consortium (BARC)-defined bleeding type 3 or 5.
Additional secondary endpoints reported by investigators have been
detailed in the Supplementary material online, Appendix.
The trial was monitored for event underreporting and event definition
consistency; no independent central event adjudication was planned.9
Statistical analysis
Kaplan–Meier method was used to estimate the cumulative rates of
events and the log-rank test was applied to compare the risk for clinical
endpoints between groups.
A hazard ratio (HR) was reported with 95% CIs based on the univari-
able and multivariable Cox regression model.
The analyses of the primary endpoint and the secondary endpoints
with tests for treatment-by-COPD status interaction were performed.
Cox proportional hazards survival model, including factors for
randomized treatment and incidence of dyspnoea event as a time-
dependent covariate, were performed with adjustment to account for dif-
ferences in relevant clinical variables between treatment groups.
In addition, as analysis of the prognostic impact of dyspnoea may be
confounded due to the fact that ticagrelor-related dyspnoea reportedly
occurs predominantly within the first 30 days of treatment11,12 and there
might be a potential overlap between factors contributing to the develop-
ment of dyspnoea and clinical events, landmark analyses were performed
for clinical outcomes from 31 days onwards in those patients who
reported dyspnoea in the first 30 days following randomization.11,12
Finally, exploratory univariable and multivariable analyses were per-
formed to compare the impact of COPD and other baseline characteris-
tics on 2-year mortality, dyspnoea occurrence and treatment adherence.
The adjustment variables were selected based on previous knowledge
and literature, i.e. the variables with clinically relevant influence on the de-
pendent variable were included in the model.5,12 In addition, variables
with P-values <0.10 by univariable analyses were added to the model.
Continuous variables were presented as mean and standard deviation
(SD) or median and interquartile range (IQR), and compared with a
standard t-test (normally-distributed continuous data), or Wilcoxon
rank-sum test. Categorical variables were presented as counts and per-
centages and compared using the Pearson’s v2 or exact test, as
appropriate.
All analyses were performed following the intention-to treat definition
using the SPSS Software (SPSS 25, IBM, Chicago, IL, USA). A two-sided P-
value of 0.05 was considered statistically significant.
Results
Between 1 July 2013 and 9 November 2015, the GLOBAL LEADERS
study enrolled and randomized 15 991 patients.9 After 23 patients
withdrew consent and formally requested their data deletion, there
were data from 7980 patients in the experimental group and 7988 in
the reference group available for analysis9 (Supplementary material
online, Figure S1).
There were 832 (5.2%) of patients identified with a history of
COPD at enrolment (Table 1 and Supplementary material online,
Table S1). Patients with COPD were older, more often presented
with stable CAD, more often had comorbidities such as diabetes,
hypertension, peripheral vascular disease, previous major bleeding,
impaired renal function, prior stroke, MI, or coronary artery bypass
grafting and were more frequently smokers, compared with non-
COPD individuals (Table 1).
Chronic obstructive pulmonary disease was associated with higher
rate of the primary endpoint (10.5% vs. 3.7%, HR 2.41, 95% CI 1.92–
3.03, Padj = 0.001), all-cause mortality, any type of stroke, BARC 3
type bleeding, and BARC 3 or 5 type bleeding (Table 2). Chronic ob-
structive pulmonary disease was identified as one of the most deter-
minant predictors of 2-year mortality (HR 2.82, 95% CI 2.20–3.62,
Padj = 0.001) in the overall GLOBAL LEADERS study (Supplementary
material online, Table S2).
Randomized treatment safety and
efficacy in chronic obstructive pulmonary
disease and non-chronic obstructive
pulmonary disease patients
Among patients with COPD, the primary endpoint occurred in 9.8%
of patients in the experimental group and in 11.1% of patients in the
reference group (HR 0.88, 95% CI 0.58–1.35, P = 0.562, Pint = 0.952)
(Table 3).
In patients with COPD allocated to the experimental arm, the
rates of all-cause death, stroke, MI, definite stent thrombosis, and
BARC 3 or 5 type bleeding were not statistically different, when com-
pared with patients treated according to the reference treatment
strategy (Table 3, Figure 1).
Treatment adherence in chronic
obstructive pulmonary disease and
non-chronic obstructive pulmonary
disease patients
Patients with COPD presented consistently lower rates of treatment
adherence, compared with patients without COPD (Table 4), that
were lower in the experimental vs. the reference treatment arm
(Supplementary material online, Table S3). By multivariable analysis,
positive COPD status at baseline was identified as one of the most
determinant negative predictors of adherence to randomized
treatment at 1 and 2 years after PCI (Supplementary material online,
Table S4).
Dyspnoea adverse event
In overall GLOBAL LEADERS cohort, up to 2 years dyspnoea was
reported as AE in 2101 patients. Chronic obstructive pulmonary
disease was identified as a significant predictor of this AE
(Supplementary material online, Tables S5 and S6).
Dyspnoea had been reported as AE more frequently among
COPD patients irrespective of treatment allocation (Figure 2).
Among those with a dyspnoea AE, median time from randomization


































































..to first dyspnoea occurrence was 32 days in COPD patients
(n = 169) and 34 days in non-COPD (n = 1942) (P = 0.672).
Analyses at the prespecified time intervals: at 30 days and 1 year
indicated higher incidence of dyspnoea in the experimental group
within the first month (in COPD: 13.1% vs. 6.2%, P = 0.001; in non-
COPD: 7.4% vs. 4.2%, P = 0.001) and within the first year (in COPD:
23.8% vs. 11.5%, P = 0.001; in non-COPD: 14.4% vs. 8.6%, P = 0.001),
but not during the second year after treatment initiation, when com-
pared with the reference group (Supplementary material online,
Figure S2).
Dyspnoea and clinical outcomes in
chronic obstructive pulmonary disease
and non-chronic obstructive pulmonary
disease patients
Multivariable adjusted HRs for experimental vs. reference treatment
strategy were not significantly different in dyspnoeic and non-dys-
pnoeic patients in overall population (Supplementary material online,
Table S7) and in patients with COPD (Table 5).
The occurrence of dyspnoea in COPD patients in the experimen-
tal group was not associated with a higher risk of primary endpoint
(Padj = 0.452), BARC 3 or 5 bleeding (Padj = 0.097) when compared
with the reference treatment group.
By landmark analysis at 30 days in the subgroup of patients with
dyspnoea AE reported within 30 days from treatment initiation, no
significant differences in the treatment effects were found with regard
to the rates of the primary endpoint, BARC 3 and 5 type bleeding
and other outcome variables beyond 1 month up to 2 years after PCI
in the overall GLOBAL LEADERS study (Supplementary material on-
line, Table S8) and specifically in COPD and non-COPD patients
(Supplementary material online, Table S9).
Discussion
This is the first study on the long-term safety and efficacy of ticagre-
lor, either as monotherapy following short 1-month DAPT or as part
of 12-month DAPT after PCI, that evaluated the impact of dys-
pnoea—a well-known drug adverse effect that may occasionally trig-
ger treatment discontinuation.
.................................................................................................
Table 1 Baseline characteristics in patients with and
without COPD
No COPD




N (%) N (%)
Age (years) (±SD) 64.4 (±10.4) 67.9 (±8.85) 0.001
Weight (kg) (±SD) 82.6 (±15.5) 82.3 (±16.7) 0.588
BMI (kg/m2) (±SD) 28.18 (±4.56) 28.34 (±5.19) 0.351
Female gender 3510 (23.2) 204 (24.5) 0.377
Stable CAD 8004 (52.9) 477 (57.3) 0.012
UA 1914 (12.6) 108 (13.0) 0.777
NSTEMI 3201 (21.1) 172 (20.7) 0.744
STEMI 2017 (13.3) 75 (9.0) 0.001
Diabetes 3785 (25.0) 253 (30.4) 0.001
Diabetes on insulin 1135 (7.5) 88 (10.6) 0.001
Hypertension 11 067 (73.4) 648 (78.4) 0.001
Hypercholesterolaemia 10 197 (69.6) 571 (69.8) 0.910
Currently smoking 3883 (25.7) 286 (34.4) 0.001
Peripheral vascular disease 891 (5.9) 114 (14.0) 0.001
Previous major bleeding 85 (0.6) 13 (1.6) 0.001
Impaired renal function 2031 (13.5) 159 (19.2) 0.001
Previous stroke 388 (2.6) 33 (4.0) 0.013
Previous MI 3490 (23.1) 220 (26.6) 0.021
Previous PCI 4933 (32.6) 288 (34.7) 0.204
Previous CABG 870 (5.8) 73 (8.8) 0.033
BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary ar-
tery disease; COPD, chronic obstructive pulmonary disease; MI, myocardial in-
farction; NSTEMI, non-ST segment elevation myocardial infarction; PCI,
percutaneous coronary intervention; STEMI, ST-segment elevation myocardial in-
farction; UA, unstable angina.
......................................... .........................................
....................................................................................................................................................................................................................
Table 2 Two-year clinical outcomes of coronary artery disease patients undergoing PCI in relation to COPD status
No COPD (N 5 15 136) COPD (N 5 832) Unadjusted Adjusted
N (%) N (%) HR (95% CI) P-value HR (95% CI) P-value
Primary endpoint 566 (3.7) 87 (10.5) 2.89 (2.31–3.62) 0.001 2.41 (1.92–3.03) 0.001
All-cause death 401 (2.6) 76 (9.1) 3.55 (2.78–4.54) 0.001 2.82 (2.20–3.62) 0.001
New Q-wave MI 173 (1.1) 13 (1.6) 1.42 (0.81–2.49) 0.227 1.34 (0.76–2.36) 0.318
Strokea 144 (1.0) 18 (2.2) 2.35 (1.44–3.84) 0.001 2.08 (1.26–3.41) 0.004
MI (site-reported) 465 (3.1) 33 (4.0) 1.33 (0.94–1.90) 0.111 1.16 (0.82–1.66) 0.402
Any revascularization 1458 (9.6) 74 (8.9) 0.94 (0.75–1.20) 0.640 0.88 (0.70–1.12) 0.305
Definite ST 124 (0.8) 4 (0.5) 0.60 (0.22–1.62) 0.312 0.55 (0.20–1.49) 0.237
BARC 3 276 (1.8) 33 (4.0) 2.25 (1.57–3.23) 0.001 1.99 (1.38–2.87) 0.001
BARC 5 40 (0.3) 6 (0.7) 2.80 (1.18–6.61) 0.019 2.34 (0.98–5.60) 0.055
BARC 3 or 5 296 (2.0) 36 (4.3) 2.29 (1.62–3.24) 0.001 2.02 (1.42–2.87) 0.001
Adjusted for the following variables: age, gender, clinical presentation, diabetes, hypertension, smoking history, previous cardiovascular disease, history of previous major bleed-
ing, impaired renal function, previous MI, stroke, CABG, and the randomized treatment strategy.
BARC, Bleeding Academic Research Consortium; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; ST, stent thrombosis.
aNot including TIA.




























The highest HR of 2-year all-cause mortality identified for baseline
COPD status in this contemporary PCI cohort—when compared
with other clinical variables—emphasizes the rationale to verify
whether the safety of ticagrelor monotherapy (after 1 month of dual
therapy with aspirin) observed for overall population is also valid in
case of particularly susceptible COPD patients.
The salient findings of the present study can be summarized as
follows:
i. Chronic obstructive pulmonary disease represents an important fac-
tor negatively impacting prognosis after PCI that was associated with
an increased rate of primary endpoint, all-cause mortality, stroke, and
bleeding at 2 years in patients with CAD undergoing PCI.
ii. Ticagrelor monotherapy after 1 month of DAPT was safe and associ-
ated with similar rate of primary endpoint, stroke, and bleeding
events when compared with 12-month DAPT in COPD and non-
COPD patients undergoing PCI.
iii. In patients with COPD undergoing PCI, ticagrelor monotherapy after
1 month of DAPT was associated with a higher risk of dyspnoea,
compared with the reference DAPT. Dyspnoea occurred mainly
within the first months following treatment initiation; there was no
significant excess of dyspnoea in the experimental group during the
second year of observation.
................................................................................. .................................................................................
....................................................................................................................................................................................................................
Table 3 Two-year clinical outcomes in coronary artery disease patients with and with COPD categorized according to
the treatment strategy











N (%) N (%) HR (95% CI) P-value N (%) N (%) HR (95% CI) P-value
Primary endpoint 302 (4.0) 264 (3.5) 0.87 (0.74–1.03) 0.099 47 (11.1) 40 (9.8) 0.88 (0.58–1.35) 0.562 0.952
All-cause death 212 (2.8) 189 (2.5) 0.89 (0.73–1.08) 0.240 41 (9.6) 35 (8.6) 0.89 (0.57–1.39) 0.604 0.996
New Q-wave MI 95 (1.3) 78 (1.0) 0.82 (0.61–1.11) 0.189 8 (1.9) 5 (1.2) 0.65 (0.21–1.98) 0.446 0.689
Strokea 71 (0.9) 73 (1.0) 1.03 (0.74–1.43) 0.857 11 (2.6) 7 (1.7) 0.66 (0.26–1.71) 0.393 0.386
MI (site-reported) 234 (3.1) 231 (3.1) 0.99 (0.83–1.19) 0.911 16 (3.8) 17 (4.2) 1.13 (0.57–2.24) 0.722 0.710
Any revascularization 750 (10.0) 708 (9.4) 0.94 (0.85–1.05) 0.260 43 (10.4) 31 (7.9) 0.75 (0.47–1.19) 0.217 0.341
Definite ST 62 (0.8) 62 (0.8) 1.00 (0.70–1.42) 0.992 2 (0.5) 2 (0.5) 1.05 (0.15–7.47) 0.960 0.963
BARC 3 139 (1.8) 137 (1.8) 0.99 (0.78–1.25) 0.913 20 (4.7) 13 (3.2) 0.68 (0.34–1.37) 0.278 0.320
BARC 5 20 (0.3) 20 (0.3) 1.00 (0.54–1.86) 0.996 4 (0.9) 2 (0.5) 0.53 (0.10–2.87) 0.457 0.482
BARC 3 or 5 147 (1.9) 149 (2.0) 1.02 (0.81–1.28) 0.898 22 (5.2) 14 (3.4) 0.67 (0.34–1.30) 0.232 0.241
The P-value for interaction for the various endpoints derives from the dichotomized analysis according to chronic obstructive pulmonary disease (COPD) at baseline. The pri-
mary endpoint was a composite of 2-year all-cause mortality or non-fatal, centrally adjudicated, new Q-wave myocardial infarction (MI).
BARC, Bleeding Academic Research Consortium; 95% CI, 95% confidence interval; HR, hazard ratio; ST, stent thrombosis.
aNot including TIA.
Figure 1 Kaplan–Meier curves for 2-year all-cause mortality (A) and Bleeding Academic Research Consortium defined bleeding type 3 or 5 (B)
categorized according to chronic obstructive pulmonary disease status and randomized treatment strategy. BARC, Bleeding Academic Research
Consortium; 95% CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.





































































.iv. Although the occurrence of dyspnoea up to 2 years could underlie
the lower treatment adherence in COPD subset, it was not associ-
ated with any differential treatment effect for the experimental ver-
sus reference treatment strategy, among patients with COPD and
without COPD.
Chronic obstructive pulmonary disease
and prognosis after percutaneous
coronary intervention
Chronic obstructive pulmonary disease has been reported to occur
approximately in 7–15% of patients with CAD and has been associ-
ated with higher rates of adverse clinical events,1–3,15 though results
of studies and meta-analyses evaluating its impact on the long-term
events remained highly heterogenous.1,15–17 In the present investiga-
tion, with the information on COPD status at baseline available in
100% of patients, this condition was identified in 5.2% of enrolled
patients who presented a three-fold higher mortality at 2 years after
PCI. This emphasizes the magnitude of adverse impact of COPD on
prognosis and further highlights the relevance of attempts to develop
more effective and safe treatment strategies for this challenging pa-
tient subgroup, demonstrated to be prescribed secondary preven-
tion therapies less frequently than non-COPD individuals.18
Nevertheless, the clinical—EuroSCORE based—definition of
COPD applied in this trial, without performing specific pulmonary
tests, could have at least partially underlie the lower prevalence of
COPD in this cohort compared with some previous studies1,15–17;
some under-diagnosis and preselection of patients with more severe
disease cannot be excluded in our investigation. Previous reports sug-
gested common under-diagnosis of COPD in patients with CAD.15
The possibility that the analysed COPD population may represent a
more clinically evident and severe COPD phenotype needs to be
considered when interpreting the almost three-fold higher 2-year
mortality after PCI in COPD patients in this study; previously
described relationship between COPD severity and mortality risk
could have affected the association between COPD status and all-
cause mortality in our cohort.19 Nevertheless, COPD definition used
in GLOBAL LEADERS has been extensively adopted previously.1,5 In
addition, it may also reflect the actual clinical daily practice, where
screening for lung diseases with pulmonary function testing in
patients undergoing PCI is not a routine approach.
An intriguing observation in this study is also a two-fold higher risk
of stroke observed among COPD patients, which corresponds with
the recent studies suggesting that COPD may be a risk factor for
stroke.20,21 A systematic review by Morgan et al.,20 found that COPD
was associated with a higher incidence of stroke, even after adjust-
ment for smoking status. The possible mechanisms underlying this as-
sociation might involve systemic inflammation, hypoxia, hypercapnia,
oxidative stress, and sympathetic activation that have been described
in pathophysiology and prognosis of both COPD and stroke.21
Another explanation could be related to overlapping risk factors for
COPD and stroke; atherosclerosis frequently coexists with COPD,
affecting both coronary and cerebral arteries.22–24 In addition, COPD
has been associated with increased arterial stiffness, independently of
smoking status, and this abnormality was not explained by systemic
endothelial dysfunction.20 The neuro-pneumonology is gaining an
increasing scientific interest nowadays.20
Chronic obstructive pulmonary disease
and experimental treatment strategy
The findings of no evidence of differential safety and efficacy of tica-
grelor monotherapy after 1-month vs. 12-month DAPT in patients
with CAD and COPD are noteworthy; indeed, a higher incidence of
dyspnoea in ticagrelor-treated patients within the PLATO study and
previously released reports from European Medicines Agency that
suggest an increased caution while prescribing ticagrelor to COPD
subjects could have prompted clinicians to avoid this antiplatelet
agent among patients with comorbidity of CAD and COPD.25 Of
note, although we analysed the COPD subgroup in the large contem-
porary PCI cohort, the study did not have a sufficient power to defin-
itely assess differential treatment effects in COPD patients. Thus, our
findings should be viewed as only hypothesis-generating and require
confirmation in larger, prospective trials.
Interestingly, in overall cohort, COPD was identified to be associ-
ated with increased risk of BARC 3 or 5 type bleedings up to 2 years
post-PCI. However, the experimental strategy including 23-month
monotherapy with potent P2Y12 antagonist was found not to be
....................................................................................................................................................................................................................
Table 4 Adherence to randomized treatment in patients with and without COPD
No COPD (n 5 15 136) COPD (n 5 832) P-value
Discharge 97.5 (14 719/15 099) 95.6 (789/825) 0.001
Follow up 1 month 96.4 (14 219/14 748) 95.4 (750/786) 0.147
Follow up 3 months 90.1 (13 112/14 556) 85.1 (655/770) 0.001
Follow up 6 months 88.7 (12 813/14 442) 82.1 (628/765) 0.001
Follow up 12 months 85.9 (12 318/14 338) 77.6 (578/745) 0.001
Follow up 18 months 85.7 (12 083/14 101) 77.5 (557/719) 0.001
Follow up 24 months 85.7 (12 233/14 268) 77.7 (558/718) 0.001
Data are shown as % (n/N).
The drug counts at the 1 month, 1 year, and 2-year time points reflect patient adherence before the protocol mandated change in antiplatelet regimen. Revascularizations and
per-protocol restart of DAPT allowed: (i) ticagrelor and aspirin for 30 days in the experimental treatment strategy group, (ii) dual antiplatelet therapy with ticagrelor and aspirin
(acute coronary syndrome, stable coronary artery disease patients already on ticagrelor or prasugrel), clopidogrel and aspirin (stable coronary artery disease patients) for
365 days in the standard treatment strategy group.
P-value derived from v2 test.






















































associated with increased rate of bleeding complications (either in
ACS or in stable CAD patients), among COPD patients undergoing
PCI. This corresponds with the recent reports suggesting altered
platelet function in CAD patients in the presence of COPD comor-
bidity.8 Nevertheless, lower treatment adherence in the experimen-
tal arm needs also to be considered when interpreting the bleeding
rates in our study.
Impact of dyspnoea
In line with prior reports, dyspnoea during ticagrelor therapy occurred
mainly within the first months from treatment onset, nevertheless, a
higher risk of dyspnoea was observed also beyond the first month of
treatment up to 2 years of follow-up.5,11 Although dyspnoea from any
cause occurred more frequently in ticagrelor-treated patients, in par-
ticular among COPD patients, it was not per se associated with
impaired prognosis. This observation may speak for the benign nature
of ticagrelor-related dyspnoea compared with other causes of dys-
pnoea such as heart failure and cardiac ischemia. These findings are in
line with the clinical outcomes in dyspnoeic and non-dyspnoeic ACS
patients treated with ticagrelor DAPT reported in the PLATO study.12
Based on previously demonstrated favourable benefit-risk profile
supporting the use of ticagrelor in patients with ACS and concomi-
tant COPD,5 and lack of significant safety signal found in the present
investigation, it appears that the discomfort of ticagrelor-related dys-
pnoea should not a priori hinder its selective adoption in this patient
subset. Nevertheless, the observed lower adherence in COPD
patients warrants watchful post-discharge compliance monitoring.
Knowledge of the anticipated adverse effects is important for
developing optimal educational programmes.26 Chronic obstructive
pulmonary disease patient subset could represent a target population
for recently developed systems aimed to improve the use of second-
ary prevention via tools to remind about medications, and, in particu-
lar, educate healthcare professionals and patients, i.e. about the
benign nature of drug-related dyspnoea,12,27 before switch to an-
other medication. Such approach has been already specifically dem-
onstrated to be effective after ACS.26
Strengths and limitations of the study
Here, we report a subgroup analysis from the largest so far trial com-
paring two antiplatelet treatment strategy (including a potent P2Y12
antagonist) with randomization at time of PCI, addressing the clinical-
ly relevant drug adverse effect—dyspnoea. However, the following
limitations have to be considered.
GLOBAL LEADERS was neutral in the primary endpoint analysis
in the overall population and the presented secondary analysis, like
the parent trial, was not powered to detect between-group differen-
ces in clinical outcomes. Secondly, no adjustments were made for
multiple comparisons, and therefore all presented results should be
viewed as only hypothesis-generating.
In addition, this study is a post hoc analysis that was not pre-
specified in the original trial design. While a specific study on new
antiplatelet strategies dedicated strictly to patients with CAD and
COPD might be considered somewhat unlikely to be undertaken by
independent research organizations or sponsors, based on the pre-
sented findings we would strongly advocate that future cardiovascu-
lar trial included more specific questions in their eCRF forms
Figure 2 The occurrence of the first dyspnoea reported as an adverse event up to 2 years categorized according to chronic obstructive pulmonary
disease status and randomized treatment strategy. 95% CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.
Kaplan–Meier estimates are reported (%).







































































addressing the diagnosis and severity of respiratory disorders such as
COPD. This could facilitate addressing the remaining large evidence
gap with regard to optimal potency and treatment scheme in this pa-
tient subset. GLOBAL LEADERS studied ticagrelor at a dose of 90-
mg twice daily and the lower dose of 60-mg twice daily may be better
tolerated whilst retaining a high level of platelet inhibition, a hypoth-
esis which could warrant further investigation.28,29 In the GLOBAL
LEADERS trial, investigator reporting was used without central adju-
dication for secondary outcomes. Thus, bias and random event mis-
classification cannot be excluded. This limitation needs to be
considered in particular when interpreting bleeding event rates.
Nevertheless, the trial was monitored for event definition consist-
ency and event under-reporting, with as many as seven on-site moni-
toring visits done at individual sites and one-fifth of clinical events
checked based on the source documentation.9 Use of site-reported
endpoints is a valid method in clinical research, especially involving
large cohorts, and well-defined and restricted categories within a
classification, such as BARC-defined bleeding type 3 to 5 when com-
pared with type 1 and 2, are anticipated to provide higher concord-
ance among sites and a central clinical event adjudication committee,
as well as higher reproducibility.
Finally, the randomization in GLOBAL LEADERS was not stratified
for presence of COPD at baseline. Nevertheless, in the present ana-
lysis, the baseline characteristics of COPD subgroups categorized
according to the treatment were balanced.
Conclusions
In this contemporary, large-scale, randomized trial, COPD was iden-
tified as the most significant clinical factor negatively impacting long-
term prognosis after PCI. Among patients with CAD with COPD vs.
those without COPD, ticagrelor monotherapy (after 1 month of tica-
grelor and aspirin) was associated with similar rates of the primary
endpoint of all-cause mortality or new Q-wave MI in the long-term
follow-up, when compared with 12-month DAPT followed by 12-
month aspirin monotherapy. Although dyspnoea was more frequent
in the experimental arm, in particular among COPD patients treated
with ticagrelor, the efficacy or safety appeared not to be affected.
Judicious interpretation of these results is needed given the post hoc
nature of this subanalysis.
Supplementary material
Supplementary material is available at European Heart Journal –
Cardiovascular Pharmacotherapy online.
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Table 5 Exploratory analyses of 2-year clinical outcomes in patients with and without COPD categorized according
to the occurrence of dyspnoea up to 2 years and the treatment strategy
No COPD (n 5 15 136) COPD (n 5 832)
After dyspnoeaa Without dyspnoea After dyspnoeaa Without dyspnoea
HR (Exp vs. Ref)
95% CI
P adj HR (Exp vs. Ref)
95% CI
P adj P int HR (Exp vs. Ref)
95% CI
P adj HR (Exp vs. Ref)
95% CI
P adj P int
Primary
endpoint
0.95 (0.56–1.62) 0.855 0.88 (0.74–1.05) 0.150 0.867 0.67 (0.24–1.90) 0.452 0.96 (0.59–1.55) 0.860 0.418
BARC 3/5 0.67 (0.36–1.25) 0.206 1.09 (0.85–1.39) 0.516 0.345 0.28 (0.06–1.25) 0.097 0.64 (0.29–1.40) 0.262 0.743
BARC, Bleeding Academic Research Consortium; COPD, chronic obstructive pulmonary disease; Exp, experimental; Ref, reference.
HRs and P-values are from Cox proportional hazards model with explanatory variable for treatment group, occurrence of first dyspnoea as an adverse event (as a time-dependent
covariate), and treatment-dyspnoea interaction and adjusted, for age, body mass index, gender, clinical presentation, diabetes on insulin, hypertension, peripheral vascular disease, pre-
vious major bleeding history, impaired renal function, impaired left ventricular ejection fraction <40%, previous myocardial infarction, and previous coronary artery bypass grafting.
aDyspnoea as an adverse event occurred in 169 patients with COPD at baseline (n = 832), and in 1932 patients without COPD at baseline (n = 15 136).
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